Article
Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz.
AIDS research and human retroviruses - 1 Aug 2007
Borroto-Esoda Katyna, Waters Joshua M, Bae Andrew S, Harris Jeanette L, Hinkle John E, Quinn Joseph B, Rousseau Frank S
Abstract excerpt
The presence of drug-associated mutations among ART-naive, HIV-1(+) patients may compromise the response to antiviral therapy. We evaluated the effect of preexisting drug-associated resistance mutations to the response in treatment-naive patients to therapy with emtricitabine (FTC) or stavudine (d4T) in combination with didanosine (ddI) and efavirenz (EFV). Study FTC-301A compared emtricitabine once daily (QD)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.